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Abstract
Purpose of Review To examine the use of positron emission tomography (PET) for imaging post-infarct myocardial inflamma-
tion and repair.
Recent Findings Dysregulated immune responses after myocardial infarction are associated with adverse cardiac remodelling
and an increased likelihood of ischaemic heart failure. PET imaging utilising novel tracers can be applied to visualise different
components of the post-infarction inflammatory and repair processes. This approach could offer unique pathophysiological
insights that could prove useful for the identification and risk-stratification of individuals who would ultimately benefit most
from emerging immune-modulating therapies. PET imaging could also bridge the clinical translational gap as a surrogate
measure of drug efficacy in early-stage clinical trials in patients with myocardial infarction. The use of hybrid PET/MR imaging,
in particular, offers the additional advantage of simultaneous in vivo molecular imaging and detailed assessment of myocardial
function, viability and tissue characterisation.
Summary Further research is needed to realise the true clinical translational value of PET imaging after myocardial infarction.
Keywords PET .Myocardial infarction . Inflammation .Molecular imaging . Non-invasive imaging . Heart failure
Introduction
Myocardial infarction is a major global cause ofmorbidity and
mortality, both due to acute complications arising at the time
of initial presentation, as well as longer-term sequelae includ-
ing chronic heart failure. After myocardial infarction, inflam-
mation and its resolution play key roles in the promotion of
healing responses and ultimately act to limit the degree of
acute cardiac injury and the severity of subsequent adverse
cardiac remodelling.
Indeed, inflammation is an automatic and necessary by-
product of ischaemic myocyte necrosis, which seeks to clear
and organise the damaged tissue. A broadly biphasic immune
response to myocardial infarction occurs, wherein an initial
‘pro-inflammatory phase,’ characterised by the sequential
mobilisation of various pro-inflammatory cell types, is follow-
ed by a ‘reparative phase’ where the main role of the immune
system is to facilitate wound healing, involving myofibroblast
proliferation, neovascularisation, fibrosis and scar formation
[1]. However, an excessive or unbalanced inflammatory re-
sponse is associated with an increased risk of long-term heart
failure [2].
In the light of the landmark CANTOS and COLCOT
trials, which established the proof-of-principle that certain
anti-inflammatory therapies can reduce cardiovascular
events in patients with prior myocardial infarction and ini-
tial data indicating an additional signal for reduction in
heart failure–related events, the tantalising prospect is thus
presented that pharmacological manipulation of immune
responses in the post-infarct period could be clinically ben-
eficial [3, 4, 5••].
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Given the variation in clinical presentations and the hetero-
geneity of inflammatory cell phenotypes at play within the
infarcted heart, it is likely that targeted immunosuppressive
therapies applied in specific high-risk patient populations
would yield far greater overall benefit than more ‘blanket’
broad-spectrum approaches that have been trialled in the past
[6].
In this regard, positron emission tomography (PET) imag-
ing presents a unique opportunity to probe and visualise mo-
lecular mechanisms occurring after myocardial infarction
in vivo, and to directly investigate the effects of novel thera-
pies on myocardial inflammation. This article provides a fo-
cused review of recent progress in the use of PET imaging for
imaging post-infarct myocardial inflammation and related
processes.
Cellular Biology of Post-infarct Inflammation
An understanding of the cellular biology of post-infarct in-
flammation is important for contextualising the significance
of cardiac PET signals, although detailed consideration of this
topic is beyond the scope of this article. The reader is directed
to more comprehensive reviews elsewhere [1, 7, 8].
The cardiomyocyte necrosis that follows cardiac ischaemia
sets in motion a chain of events closely linked to immune
activation and resolution, which ultimately results in the for-
mation of stable fibrotic scar tissue. However, if this balanced
and coordinated immune response fails, uncontrolled initial or
resurgent inflammation, fuelled by dysregulation of the mono-
nuclear phagocytic network, can contribute to the risk of de-
veloping long-term heart failure [9].
In the initial pro-inflammatory phase, neutrophils are
among the first leucocytes to migrate to the site of injury
whereupon they phagocytose cellular debris, degrade extra-
cellular matrix via the release of matrix metalloproteinases
and generate reactive oxygen species. Monocytes are also
recruited from the splenic reservoir and bone marrow via ad-
renergic signalling, whereupon they differentiate into tissue
macrophages and likewise undertake phagocytosis, proteoly-
sis and promote inflammation through generation of reactive
oxygen species and secretion of pro-inflammatory cytokines
(e.g. IL-1β, IL-6 and TNFα). Monocyte recruitment occurs as
early as 30 min after the onset of ischaemia and up to 40% of
the monocytes recruited within the first 24 h originate from the
spleen [10, 11]. B and T lymphocytes and natural killer cells
are also crucial components of the initial and subsequent in-
flammatory responses. In particular, T regulatory cells help
direct the transition from post-infarct inflammation towards
resolution [12].
In mouse models, flow cytometry performed after coronary
ligation has shown that pro-inflammatory Ly-6Chi monocytes
(analogous to classical CD14+CD16− and intermediate
CD14+CD16+ monocytes in humans), which have a life span
of about 20 h, predominate at days 1–4 post-infarction [13].
By day 5–14 post-infarction, through a combination of differ-
entiation and switch from CCR2 to CXC3CL1-mediated re-
cruitment, these cells are replaced by a predominance of Ly-
6Clo monocytes (analogous to non-classical CD14intCD16+
monocytes in humans), which give rise tomacrophages whose
secretory cytokine profile includes IL-10, TGFβ and VEGF.
These cytokines exert anti-inflammatory actions including
downregulation of Th1 cell responses, and promotion of an-
giogenesis and fibrosis through interactions with endothelial
cells and fibroblasts, respectively. This well-characterised
transition in monocyte phenotype was also observed in a hu-
man post-mortem study [14]. This study showed increased
pro-inflammatory CD14+CD16− cells in the infarct border
zone during the acute inflammatory phase, and comparable
numbers of CD14+CD16− and non-classical CD14+CD16+
cells in the infarct core at later time points, which coincided
with depletion of splenic monocytes. Although several studies
have shown different correlations with peripheral blood
monocytes in patients with myocardial infarction, the role of
non-classical monocytes in this context remains largely
unknown.
In another study of 36 patients, increased peak levels of
peripheral CD14+CD16− monocytes measured after acute
myocardial infarction were negatively associated with the
likelihood of longer-term left ventricular functional recovery
[15]. Increased leukocyte concentration was also associated
with a greater incidence of heart failure hospitalisations in a
study of 16,940 men from the general population without
prior history of myocardial infarction or stroke enrolled in a
cardiovascular screening programme in Sweden [16]. In mice,
attenuation of monocyte recruitment to the ischaemic myocar-
dium achieved by B cell depletion and silencing of endothelial
cell adhesion molecules or the monocyte chemokine receptor
CCR2 were, conversely, associated with preserved ejection
fraction post-infarct [17–19]. The beneficial actions of
angiotensin-converting enzyme inhibition on left ventricular
function after myocardial infarction may also in part be related
to reduction in recruitment of splenic-derived monocytes to
the healing myocardium [20].
Divergent subsets of cardiac CCR2+ and CCR2− macro-
phages have also been described [21]. While monocyte-
derived cardiac CCR2+ macrophages are pro-inflammatory,
tissue-resident CCR2− macrophages have non-redundant
cardioprotective roles in tissue remodelling and cardiac regen-
eration, and largely self-renew via local proliferation [22].
During post-myocardial infarction remodelling, increases in
cardiac macrophages occurring in the remote myocardium
are due to local proliferation and to a lesser extent monocyte
recruitment [18].
Lower numbers of CCR2+ macrophages have been associ-
ated with improvement in left ventricular systolic function in
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patients with severe heart failure undergoing left ventricular
assist device implantation, as has also been shown inmice [23,
24]. In other murine studies, directing cardiac macrophage
populations towards a reparative phenotype using either small
interfering RNA directed at the transcription factor IRF5, or
subcutaneous IL-10 injection, led to improvements in left ven-
tricular function post infarct [25, 26].
Traditionally, the functions of the broadly divergent mac-
rophage types in the post-infarct myocardium have been as-
cribed to ‘M1-like’ and ‘M2-like’ macrophages. However, it
is important to note that this classification system is based on a
spectrum of in vitro activation profiles rather than the broader
transcriptional repertoire of macrophages that is now known
to exist [27]. There is also incomplete overlap with M1 and
M2 markers in cardiac CCR2+/CCR2− macrophages [23].
Indeed, data from studies that have applied unbiased high-
throughput sequencing techniques have revealed a wide-
range of both resident and monocyte-derived macrophage
sub-types that co-exist in the infarct, peri-infarct and remote
myocardium [28]. The occurrence of macrophage plasticity
and the role of metabolic and epigenetic reprogramming of
multi-level systemic immune cell activation add to the level
of complexity [29].
Apoptosis and the clearance of apoptotic cells
(efferocytosis) are another important component of post-
infarction damage resolution, and experimental suppression
of efferocytosis has been shown to result in larger myocardial
infarct size and greater systolic dysfunction [30].
Because these key inflammatory processes are vital for
determining the extent of myocardial damage and likelihood
of long-term heart failure after myocardial infarction, there is a
role for molecular imaging techniques such as PET to study
these disease mechanisms in efforts to inform the design and
use of new therapeutic strategies for ischaemic heart failure.
PET Tracers for Imaging Post-infarct
Inflammation
Molecular imaging of myocardial inflammation with PET of-
fers the advantage of enabling the in situ visualisation, in real-
time, of post-infarction processes. Moreover, by utilising nov-
el PET tracers that are specific for particular inflammatory cell
types or processes, individual components of the initial in-
flammatory and subsequent healing responses can potentially
be interrogated.
18F-FDG Imaging After Myocardial Infarction
18F-fluorodeoxyglucose (18F-FDG) is the most commonly
used PET tracer for inflammation imaging in clinical medi-
cine, and several studies of post-infarct imaging testify to the
general feasibility of this imaging approach.
Using PET/CT in a mouse model of myocardial infarction,
one study showed increased 18F-FDG uptake within infarcted
myocardium on day 5 post-infarct compared to control ani-
mals, which co-localised with delayed gadolinium enhance-
ment on MRI [31]. The highest 18F-FDG signals were ob-
served at the infarct border zone, which corresponded with
the site of peak monocyte/macrophage recruitment in some
cases. Increased tracer uptake was also confirmed in
monocytes/macrophages isolated from the infarcted mouse
hearts, compared to the surrounding infarct tissue.
Similar findings for 18F-FDG have been observed in sev-
eral clinical studies. For example, one study including 15 pa-
tients imaged within 7 days of a first myocardial infarction
showed the metabolic rate of 18F-FDG uptake to be increased
in infarcted versus remote myocardium [32]. The PET signal
was higher in myocardial segments with late gadolinium en-
hancement and oedema, versus oedema alone in this study. In
5 control patients with previous stable myocardial infarction, a
reverse pattern was observed, with lower 18F-FDG uptake in
the chronic infarct compared to remote zone. Another study
that analysed 39 patients with ST-segment elevation myocar-
dial infarction found that elevated infarct-related 18F-FDG up-
take in the first week after myocardial infarction was associ-
ated with an increased likelihood of left ventricular impair-
ment on MRI after 6 months, independent of infarct size
[33•]. In this study, 18F-FDG uptake in the infarcted myocar-
dium was also correlated with 99mTc-sestamibi SPECT-
defined area at risk and peripheral blood counts of
CD14highCD16+ monocytes.
However, despite these encouraging data, myocardial im-
aging using 18F-FDG is nonetheless challenging due to avid
physiological background uptake. Pre-scan patient prepara-
tion for cardiac 18F-FDG imaging requires cumbersome myo-
cardial suppression protocols, which are often ineffective. The
effect of dietary manipulation on the already altered metabolic
state of viable, post-ischaemic cardiac myocytes is also un-
known. Moreover, while 18F-FDG is a clinically useful mea-
sure of metabolic activity in inflammatory cells such as mac-
rophages in several cardiovascular diseases, its uptake is not
cell-specific.
To overcome these limitations, several novel PET tracers
that could potentially provide more specific markers of in-
flammation and/or related cellular processes than 18F-FDG
have been investigated for use in myocardial imaging (Fig. 1
and Table 1).
Tracers for Imaging Post-infarct Inflammation
Aside from 18F-FDG, other PET tracers that have been inves-
tigated for post-infarct myocardial inflammation imaging ei-
ther bind cell-surface receptors that are known to be expressed
on macrophages and other inflammatory cells, or are more
selectively taken up by metabolically active inflammatory
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cells than 18F-FDG. Importantly, these tracers exhibit lower
background myocardial activity than 18F-FDG, offering the
potential for better differentiation of focal myocardial signals
without the need for dietary myocardial suppression. While
much of the key research in the field has so far been conducted
in preclinical animal models, a summary of novel PET tracers
applied in clinical studies is shown in Table 2.
Translocator Protein Receptor The translocator protein
(TSPO) receptor is situated in the outer mitochondrial mem-
brane and is expressed in activated mononuclear cells and
other inflammatory cells. In a translational study, PET imag-
ing with the TSPO tracer 18F-GE180 revealed elevated myo-
cardial TSPO signals at 1 week post-coronary artery ligation
in mice, which co-localised to CD68+ inflammatory macro-
phages in the infarct [38•]. Early increases in TSPO PET sig-
nals after the infarct were predictive of subsequent adverse left
ventricular remodelling at 8 weeks. In vitro data also demon-
strated that M1 macrophages exhibited 7-fold higher TSPO
uptake compared toM2macrophages. Treatment of mice with
an angiotensin-converting enzyme inhibitor also resulted in
lower TSPO signal in the infarct compared to control animals.
In the same study, feasibility of clinical imaging was shown in
3 patients with myocardial infarction who were found to have
elevated infarct-related TSPO signal compared with healthy
controls. Interestingly, changes in neuroinflammation
detected by TSPO occurred in parallel to changes in infarct-
related myocardial signals in both mice and patients.
Somatostatin Receptor Subtype-2 Upregulation of somato-
statin receptor subtype-2 (SST2) occurs in activated macro-
phages, offering another novel inflammation imaging target
that may be useful in range of cardiovascular diseases [58, 59].
Among the clinically available somatostatin receptor PET
tracers, 68Ga-DOTATATE has the highest binding affinity
for SST2. Although one preclinical study observed rapid
blood clearance of 68Ga-DOTATATE following injection
with no myocardial binding after coronary ligation in mice,
initial clinical data appears more promising for this approach.
In a study that included 6 patients with myocardial infarction
who were imaged using the somatostatin receptor PET tracer
68Ga-DOTATOC within 3 to 10 days of symptoms, focal
myocardial signals were observed in all patients [39].
Overall, there was good concordance between 68Ga-
DOTATOC signal and infarcted myocardial segments with
late gadolinium enhancement and oedema on MRI. In an ex-
ploratory post hoc analysis of 12 patients with myocardial
infarction who underwent prospective cardiovascular 68Ga-
DOTATATE PET imaging, infarct-related myocardial SST2
signals were increased in patients with recent myocardial in-
farction [34] (Fig. 1). In this study, focal myocardial 68Ga-
DOTATATE signals were observed in damaged myocardial
Fig. 1 PET imaging of inflammation and related processes after
myocardial infarction. Left panels: tracers for imaging inflammatory
cells. Top A 68Ga-DOTATATE (SST2) PET-CT image demonstrating
residual inflammation (arrow) in B partially viable myocardium with
subendocardial infarct (dashed arrow), bordering full thickness scarring
(asterisk) confirmed by late gadolinium enhancement magnetic
resonance imaging, 4 years after a left anterior descending artery MI.
(Reproduced from: J Am Coll Cardiol. 2019;73:2489–91; doi: 10.1016/
j.jacc.2019.02.052; Creative Commons user license https://
creativecommons.org/licenses/by/4.0/) [34]. Bottom An apical
myocardial infarct (arrows), visualised using contrast-enhanced
multishot inversion recovery turbo field echo cardiac MRI (C), 68Ga-
pentixafor (CXCR4) PET (D) and fused PET-CT (E). (Reprinted from
JACC Cardiovasc Imaging. 2015;8:1466–8, with permission from
Elsevier) [35]. Right panels: tracers for imaging post-infarct myocardial
processes related to inflammation. Top 18F-Fluciclatide (angiogenesis)
PET-CT (F) and MRI images (G) of an antero-septal infarct.
(Reproduced from: Heart. 2016;103:607–15; doi: 10.1136/heartjnl-
2016-310115; Creative Commons user license https://creativecommons.
org/licenses/by/4.0/) [36•]. Bottom 68Ga-FAPI (fibrosis) imaging. In this
patient with thyroid cancer, whole-body PET-CT imaging reveals 68Ga-
FAPI uptake in the left ventricle as shown on the PET (H) and fused PET-
CT (I) images. (Reproduced from: J Nucl Cardiol. 2020;1–10; doi: 10.
1007/s12350-020-02307-w; Creative Commons user license https://
creativecommons.org/licenses/by/4.0/) [37]
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segments with echocardiographic regional wall motion abnor-
malities in patients with old myocardial infarction. Infarct-
related 68Ga-DOTATATE signals were also correlated with
increased metabolic bone marrow activity measured by 18F-
FDG PET. A pre-specified sub-study of an ongoing prospec-
tive observational study aiming to characterise the natural his-
tory of coronary and myocardial 68Ga-DOTATATE inflam-
matory signals after myocardial infarction (ClinicalTrials.gov
Identifier: NCT04073810) will shed further light on these
initial observations.
C-X-C Chemokine Receptor Type-4 The C-X-C motif chemo-
kine receptor type 4 (CXCR4) is expressed on the surface of
several inflammatory cell types, including macrophages, neu-
trophils and lymphocytes. In one study, uptake of the
CXCR4-targeted tracer 68Ga-pentixafor peaked in the infarct
region 3 days post-myocardial infarction in mice and
corresponded with a flow cytometry-based peak of circulating
CD45+ leukocytes and histological staining of macrophages
and granulocytes within the infarct [40]. As with the TSPO
ligand, CXCR4 PET signals in mouse infarcts were also at-
tenuated by pre-administration of enalapril. As part of the
same study, feasibility of clinical imaging was shown in 12
patients who underwent 68Ga-pentixafor PET/CT and cardiac
MRI within 8 days of an ST-segment elevation myocardial
infarction. In these patients, CXCR4 PET signals were higher
in the infarct region than remote myocardium and were corre-
lated with CXCR4 signals in the bone marrow and spleen.
In a small clinical study of 7 patients with myocardial in-
farction who underwent 68Ga-pentixafor PET imaging within
5–10 days of the event, only 3 of the 7 patients showed focal
uptake in the infarct as defined by MRI [35] (Fig. 1). Another
study showed infarct-related 68Ga-pentixafor uptake in 17 of
22 patients imaged within the first 2 weeks after the event
[41]. In this study, myocardial CXCR4 signals were inversely
associated with time from symptoms to scanning and were
also negatively associated with scar volume assessed by late
gadolinium MRI at a median 4-month follow-up. Residual
myocardial 68Ga-pentixafor uptake at this late timepoint could
represent leucocyte involvement in the healing process, but
without direct histological comparison, this notion remains
speculative.
In another translational study involving 180 mice, persis-
tent myocardial 68Ga-pentixafor PET signals occurring be-
yond 3 days after coronary ligation were observed more often
in animals that died of left ventricular rupture than those who
survived and were associated with worse cardiac function at 6
weeks [42•]. Moreover, the incidence of left ventricular rup-
ture was reduced by administration of a CXCR4 blocking
agent within the first 3 days post-MI. When compared to his-
tology, myocardial 68Ga-pentixafor uptake co-localised with
CD68+ inflammatory cells and was also associated with in-
creased numbers of both Ly6Chigh and Ly6Clow peripheral
monocyte counts. These findings were confirmed in 50 pa-
tients with myocardial infarction. In these patients, CXCR4
signals showed a weak-to-moderate inverse correlation with
left ventricular function at baseline and after follow-up of
approximately 7 months.
Another study showed increased 68Ga-pentixafor uptake in
mediastinal lymph nodes in patients after myocardial infarc-
tion because of T cell accumulation [60]. The findings of this
study support a potential role for CXCR4 blockade post-
infarction as a means of mobilising T-regulatory cells to the
injured myocardium, which have been shown to limit adverse
cardiac remodelling in pre-clinical models [61].
Chemokine Receptor Type-2 C-C chemokine receptor type 2
(CCR2) is another important inflammatory cell marker in-
volved in monocyte/macrophage recruitment, which has been
evaluated for imaging myocardial inflammation using PET. In
an ischaemia-reperfusion heterotopic heart transplantation
mouse model, the PET tracer 64Cu-DOTA-ECL1i was shown
to bind CCR2+ monocytes and macrophages within donor
hearts, demonstrating increased tracer uptake compared to na-
tive hearts [43]. Specific autoradiographic binding was also
confirmed in human myocardial specimens. Comparable
myocardial PET signal intensity was observed with the
64Cu-labelled tracer to data from a previous study on 68Ga-
DOTA-ECL1i [44].
As CCR2+ macrophage depletion has demonstrated bene-
ficial effects on cardiac function post-infarction in mouse
models, CCR2-targeted PET tracers could also be useful for
the clinical evaluation of CCR2 inhibitors in future early-stage
clinical trials [24].
Macrophage Phagocytosis 64Cu-Macrin is a 20-nm spherical
dextran nanoparticle tracer designed specifically to target
macrophages. In a preclinical study, 64Cu-Macrin was shown
to report on the accumulation of macrophages within the in-
farcted myocardium in experiments using mice, rabbits and
pigs [45•]. Increases in lung and cardiac 64Cu-Macrin PET
signals were also observed in mouse models of sepsis and
pneumonia, in newborn mice exhibiting higher macrophage
content than adults, and in atherosclerotic plaques in rabbits.
Comparison of a near-infrared fluorescent version of the nano-
particle with flow cytometry and confocal staining showed
that the tracer uptake occurred predominately in MHCIIhigh
CCR2high tissue macrophages. In contrast, 64Cu-Macrin up-
take was negligible in neutrophils, fibroblasts and endothelial
cells.
Amino Acid Metabolism Radio-labelled amino acid ana-
logues represent another potential approach for imaging
the metabolic activity of inflammatory cells after myocar-
dial infarction. For example, the PET tracer 11C-methio-
nine is thought to accumulate in macrophages, but not
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healthy myocytes. In a small clinical study, 11C-methio-
nine PET was performed in 9 patients with left anterior
descending artery myocardial infarctions treated by percu-
taneous coronary intervention, within 2 weeks of the event
[47]. In these patients, increased 11C-methionine signal
was observed in areas of low or absent 201Thallium
SPECT and 18F-FDG PET signal in the myocardium indi-
cating tissue infarction, and subsequent reductions in 11C-
methionine signals were seen in 2 patients imaged at 3 or 6
months. In another study, 11C-methionine PET imaging
performed in mice showed increased tracer uptake in the
infarcted myocardium at day 3 post-coronary ligation,
compared to the remote myocardium and healthy control
animals, which was associated with macrophage infiltra-
tion on histology [48]. The 11C-methionine PET signal
declined by day 7 and was also inhibited by treatment with
anti-integrin antibodies that lowered macrophage content.
In the same study, 11C-methionine uptake was shown to
occur more in M1 than M2 polarised macrophages. Further
spatiotemporal profiling of infarct-related 14C-methionine
signal was investigated in a rat model, which showed peak
tracer uptake occurring at days 3 to 7 post-infarct, with a
gradual decline until day 28 [49]. Lower tracer uptake oc-
curring at later time points was felt to reflect myofibroblast
activity or neoangiogenesis, rather than acute inflammation
per se.
Tracers for Imaging Post-infarct Myocardial Processes
Related to Inflammation
Neoangiogenesis Integrin avβ3 expressed by endothelial
cells (as well as macrophages and other cells) has been
examined for use as a PET imaging target for detecting
neoangiogenesis. In one study, myocardial accumulation
of the avβ3-targeted PET tracer
18F-Galacto-RGD was ob-
served from 3 days post-infarction in rats, with peak tracer
uptake in the infarct between 1 and 3 weeks [50]. avβ3 PET
signal intensity was associated with increased histological
vascular density in post-infarct tissue specimens. In a clin-
ical study, increased myocardial avβ3 PET signal was also
observed using 68Ga-PRGD2 in 20 out of 23 patients im-
aged within 1 week after their event [51]. Another clinical
study showed that 18F-Fluciclatide, which also binds avβ3,
showed higher PET signals at the site of acute infarction in
patients within 2 weeks of their event, compared to remote
myocardium and patients with old infarction or healthy
volunteers [36•] (Fig. 1). In this study, baseline 18F-
Fluciclatide uptake was also associated with an increased
probability of subsequent functional left ventricular recov-
ery after 9 months.
Cardiac Fibrosis Experimental tracers have been tested for im-
aging myofibroblast activity after myocardial infarction,
which bind fibroblast activation protein. In one study per-
formed in a rat model of infarction, 68Ga-FAPI-04 PET sig-
nals occurring at day 6 post-infarction were highest at the
infarct border zone, which co-localised with histological
myofibroblast staining [52]. A retrospective analysis of clini-
cal images from 32 patients who underwent prior 68Ga-FAPI
PET imaging for cancer staging showed focal myocardial
68Ga-FAPI uptake in patients with previous history of coro-
nary artery disease and impaired left ventricular function [37]
(Fig. 1). A similar association between focal cardiac 68Ga-
FAPI PET uptake and cardiovascular risk factors was found
in another retrospective study of 229 patients with cancer [53].
Apoptosis and Microcalcification Other pathogenic processes
occurring after myocardial infarction that have been targeted
for molecular imaging with PET tracers include apoptosis and
microcalcification. Indeed, given the importance of
efferocytosis on post-infarct repair and inflammation resolu-
tion, detection of defective or delayed clearance of apoptotic
cells by PET imaging could represent an important imaging
target. A study of the novel apoptosis tracers 18F-ML-10 and
18F-ML-8 demonstrated focal infarct-related myocardial trac-
er accumulation on days 1 to 3 after coronary ligation in rats in
regions devoid of 18F-FDG uptake and histologically con-
firmed apoptosis [54]. In this study, ex vivo binding assays
showed that 18F-ML-8 was taken up by apoptotic, but not
necrotic or normal cells, presenting a potential advantage over
Annexin V and synaptotagmin-I targeted SPECT tracers,
which bind exposed phosphatidylserine in both apoptotic
and necrotic cells.
Microcalcification is also thought to occur as part of the
healing process after myocardial infarction. In one study of 10
patients, signal from the PET tracer 18F-NaF, which binds to
areas of microcalcification and exposed hydroxyapatite in ath-
erosclerosis, was increased more in areas of myocardial in-
farction with scar than the remote myocardium [55].
However, areas of increased myocardial 18F-NaF PET signals
occurring 1 day after myocardial infarction in rats were found
to closely match histological markers of apoptosis, but not
calcification.
Other Molecular Targets Among the other molecular targets
that have been examined for post-myocardial infarction PET
imaging is glucagon-like peptide-1 (GLP-1) [56]. This target
is of particular interest as inhibition of the GLP1 receptor has
been associated with improved cardiovascular outcomes in
multiple clinical trials of patients with diabetes mellitus, al-
though its effects on myocardial function are less clear [62].
Novel tracers for myocardial perfusion/infarct imaging, such
as 68Ga-DOTA chelate, and for imaging myocardial oxidative
metabolism, such as 11C-acetate, have also been investigated
in preclinical studies and could be useful in this setting [63,
64].
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Future Directions
Among the potential clinical translational applications of post-
infarct myocardial PET imaging are as follows: (i) to identify and
risk-stratify patients with maladaptive initial or ‘residual’ inflam-
matory responses contributing an increased likelihood of long-
term heart failure, and (ii) to inform the design and use of emerg-
ing immune-modulatory therapies for cardiovascular disease.
This type of mechanistic research may also yield valid, non-
PET biomarkers that can be more easily rolled out in the clinic.
Several preclinical studies have shown that PET imaging, for
example with tracers targeting TSPO or CXCR4, can quantify
changes in myocardial inflammation after treatment with con-
ventional heart failure therapies, such as angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers [38•, 40, 65,
66]. In another study, treatment with a novel NOD-like receptor
protein 3 inflammasome inhibitor MCC950 in mice reduced
infarct-related 18F-FDG inflammatory signals, along with histo-
logical grading of M1 macrophage and neutrophil infiltration,
and improved myocardial viability after myocardial infarction
[67]. Results of future clinical trials using PET imaging to exam-
ine the effects of novel therapies for modulating ischaemic myo-
cardial inflammation are awaited.
Multi-tracer studies can potentially help further tease out in-
dividual inflammatory pathways or healing responses to improve
the precision of therapeutic targeting after myocardial infarction.
For example, a study published as an abstract showed that pe-
ripheral macrophage depletion in mice resulted in reduced 18F-
GE180 infarct-related uptake at day 7 compared to control myo-
cardial infarction due to lower CD68+ macrophage content, but
increased 68Ga-pentixafor signal because of sustained recruit-
ment of Ly6G+ neutrophils, as well as active calcification of
intracavity thrombus detected by 18Na-NaF [68].
Moreover, the use of multi-modality multi-parametric imag-
ing, and in particular hybrid PET/MRI, offers the ability to com-
bine molecular imaging of inflammation and adjunct processes
with detailed tissue characterisation. The potential value of this
combined approach was shown in a study of 25 patients who
underwent hybrid 18F-FDG PET/MRI within 5 days of
revascularisation formyocardial infarction [69]. This study found
that although changes in 18F-FDG uptake, T1 mapping and ex-
tracellular volume tended to overlap anatomically within the in-
farcts of individual patients, a lack of quantitative correlation
meant that these measures were reporting on different underlying
biological processes or tissue properties. In another preclinical
study, dual-imagingwith 18F-Macroflor PET (a dextran nanopar-
ticle similar to 18F-Macrin) and MRI with MPO-Gd, which de-
tects myeloperoxidase activity in neutrophils and Ly-6Chigh
monocytes, was performed at day 2 and 6 post-infarct in mice.
This study showed divergent temporal changes in PET andMRI
signals in keeping with the well-characterised biphasic
monocyte/macrophage phenotypic response after myocardial in-
farction [46].
Conclusions
Dysregulated post-infarction inflammation and remodelling
confer adverse outcomes in patients after myocardial infarc-
tion. PET imaging of these processes can potentially be
utilised in both the development and deployment of novel
immunomodulatory therapies for this indication. Further re-
search efforts should be directed towards realising the full
potential of these novel molecular imaging techniques.
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